Riluzole, neuroprotection and amyotrophic lateral sclerosis

BC Cheah, S Vucic, AV Krishnan… - Current medicinal …, 2010 - ingentaconnect.com
Amyotrophic lateral sclerosis (ALS) is a universally fatal neurodegenerative disease of the
human motor system. Aetiological mechanisms implicated in the development of ALS have …

Glial cells—The strategic targets in amyotrophic lateral sclerosis treatment

T Filipi, Z Hermanova, J Tureckova, O Vanatko… - Journal of clinical …, 2020 - mdpi.com
Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease, which is characterized by
the degeneration of motor neurons in the motor cortex and the spinal cord and subsequently …

Long‐term survival in amyotrophic lateral sclerosis: A population‐based study

E Pupillo, P Messina, G Logroscino, E Beghi… - Annals of …, 2014 - Wiley Online Library
Objective To determine the long‐term survival in amyotrophic lateral sclerosis (ALS) and
identify predictors of prolonged survival in a population‐based cohort of newly diagnosed …

Transplantation of spinal cord–derived neural stem cells for ALS: analysis of phase 1 and 2 trials

JD Glass, VS Hertzberg, NM Boulis, J Riley, T Federici… - Neurology, 2016 - AAN Enterprises
Objective: To test the safety of spinal cord transplantation of human stem cells in patients
with amyotrophic lateral sclerosis (ALS) with escalating doses and expansion of the trial to …

Serum C-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis

C Lunetta, A Lizio, E Maestri, VA Sansone… - JAMA …, 2017 - jamanetwork.com
Importance Various factors have been proposed as possible candidates associated with the
prognosis of amyotrophic lateral sclerosis (ALS); however, there is still no consensus on …

Qualitative measures that assess functional disability and quality of life in ALS

SL Hartmaier, T Rhodes, SF Cook, C Schlusser… - Health and quality of life …, 2022 - Springer
Background Selection of appropriate trial endpoints and outcome measures is particularly
important in rare disease and rapidly progressing disease such as amyotrophic lateral …

A phase II− III trial of olesoxime in subjects with amyotrophic lateral sclerosis

T Lenglet, L Lacomblez, JL Abitbol… - European journal of …, 2014 - Wiley Online Library
Background and purpose To assess the efficacy and safety of olesoxime, a molecule with
neuroprotective properties, in patients with amyotrophic lateral sclerosis (ALS) treated with …

Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials

R Balendra, A Jones, N Jivraj, IN Steen… - Journal of Neurology …, 2015 - jnnp.bmj.com
Objectives The use of clinical staging in the fatal neurodegenerative disease amyotrophic
lateral sclerosis would have value in optimising future therapeutic trials. We aimed to use …

Defining SOD1 ALS natural history to guide therapeutic clinical trial design

T Bali, W Self, J Liu, T Siddique, LH Wang… - Journal of Neurology …, 2017 - jnnp.bmj.com
Importance Understanding the natural history of familial amyotrophic lateral sclerosis (ALS)
caused by SOD1 mutations (ALSSOD1) will provide key information for optimising clinical …

Sleep-disordered breathing in neuromuscular disease: diagnostic and therapeutic challenges

LS Aboussouan, E Mireles-Cabodevila - Chest, 2017 - Elsevier
Normal sleep-related rapid eye movement sleep atonia, reduced lung volumes, reduced
chemosensitivity, and impaired airway dilator activity become significant vulnerabilities in …